Search research articles
Contact Us
Filters
Showing results (161-170 of 178) with videos related to
Page
of 18
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 7, 2026
A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study
L Garrigós, M Ruiz-Borrego, J M Pérez-García, et al.
Nature Communications
|
May 13, 2022
CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer
M G Filippone, D Gaglio, R Bonfanti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 20, 2026
Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial
M Dugo, C-S Huang, D Egle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2021
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy
G Jerusalem, S Farah, A Courtois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2008
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
M Untch, R D Gelber, C Jackisch, et al.
Breast Cancer Research : BCR
|
January 24, 2025
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
A DeMichele, A C Dueck, D Hlauschek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 28, 2023
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women
S J Luen, G Viale, S Nik-Zainal, et al.
ESMO Open
|
October 17, 2024
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]
E de Azambuja, M Piccart-Gebhart, S Fielding, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 2, 2026
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer
P A Francis, O Pagani, G F Fleming, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 6, 2007
Guidelines on the standards for the training of specialised health professionals dealing with breast cancer
L Cataliotti, C De Wolf, R Holland, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 178) with videos related to
Sort By:
Page
of 18
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 7, 2026
A chemotherapy-free, pathological response-adapted strategy using trastuzumab-pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study
L Garrigós, M Ruiz-Borrego, J M Pérez-García, et al.
Nature Communications
|
May 13, 2022
CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer
M G Filippone, D Gaglio, R Bonfanti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 20, 2026
Longitudinal transcriptomic profiling identifies predictors of response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: results from the NeoTRIPaPDL1 trial
M Dugo, C-S Huang, D Egle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2021
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy
G Jerusalem, S Farah, A Courtois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2008
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
M Untch, R D Gelber, C Jackisch, et al.
Breast Cancer Research : BCR
|
January 24, 2025
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
A DeMichele, A C Dueck, D Hlauschek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 28, 2023
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women
S J Luen, G Viale, S Nik-Zainal, et al.
ESMO Open
|
October 17, 2024
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]
E de Azambuja, M Piccart-Gebhart, S Fielding, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 2, 2026
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer
P A Francis, O Pagani, G F Fleming, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 6, 2007
Guidelines on the standards for the training of specialised health professionals dealing with breast cancer
L Cataliotti, C De Wolf, R Holland, et al.
Page
of 18